3-ingenyl angelate

08/01/2019 - "Our study shows that ingenol mebutate is highly efficacious field treatment for actinic keratosis."
01/01/2012 - "In human studies, ingenol mebutate achieved high clearance of actinic keratosis on the head and body after 2-3 consecutive daily treatments when measured by complete or partial clearance of lesions. "
06/01/2013 - "To assess 12-month recurrence rates and safety associated with ingenol mebutate gel treatment in patients who previously had achieved complete clearance of actinic keratoses. "
10/01/2017 - "OBJECTIVE: To determine whether actinic keratosis and photodamaged perilesional areas (field cancerization) treated successfully with topical ingenol mebutate gel 0.015% remained clear one year later, and to treat actinic keratosis and perilesional skin not treated one year earlier. "
01/01/2017 - "CONCLUSION: ingenol mebutate gel 0.015% applied to a less than 100cm2 area of the chest once daily for three consecutive days reduced the actinic keratosis count and significantly improved signs of photoaging with high patient satisfaction and good tolerability."

01/01/2012 - "While the mechanism of action of ingenol mebutate is not fully understood, in vitro and in vivo studies using tumor models indicate it has multiple mechanisms. "
11/01/2017 - "We examined the combination of the FDA-approved drug ingenol-3-angelate (PEP005) with epigenetic drugs as a rational therapeutic approach for KSHV-mediated malignancies. "
01/01/2016 - "Ingenol mebutate treatment induces a pronounced infiltration of neutrophils, which have been shown to have anti-cancer activity in mice. "
09/22/2015 - "It has been shown that ingenol-mebutate inhibits the growth of cancer cells or induces tumor cell death through pro-apoptotic effects. "
01/01/2015 - "Ingenol mebutate: from common weed to cancer cure."

01/01/2017 - "Dermoscopic monitoring of efficacy of ingenol mebutate in the treatment of pigmented and non-pigmented basal cell carcinomas."
04/01/2023 - "Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study."
10/01/2020 - "Superficial Basal Cell Carcinoma of the Face Successfully Treated with Ingenol Mebutate 0.05% Gel: Case Report and a Review of the Literature."
05/01/2020 - "Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma."
03/01/2020 - "Basal cell carcinomas (BCCs) have previously been treated off-label with ingenol mebutate (IM). "

11/02/2022 - "Ingenol mebutate (IM) is highly effective in the treatment of human papillomavirus (HPV)-induced anogenital warts (AGW) leading to fast ablation within hours. "
01/01/2018 - "Topical ingenol mebutate is effective against plantar warts in immunocompromised patients."
06/01/2016 - "Ingenol mebutate gel is effective against anogenital warts - a case series in 17 patients."
05/01/2018 - "An exploratory, prospective, open-label trial of ingenol mebutate gel 0.05% for the treatment of external anogenital warts."
01/01/2018 - "An open-label exploratory study evaluating the efficacy and safety of ingenol mebutate gel 0.05% for the treatment of verruca vulgaris."

05/01/2013 - "Premarketing trials for treatment of nonmelanoma skin cancers also showed promising results for ingenol mebutate. "
04/01/2015 - "Could ingenol mebutate be useful in managing nonmelanoma skin cancers?"
05/01/2013 - "Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers."
11/01/2017 - "In conclusion, the thesis highlights ingenol mebutate's potential as a prophylactic remedy for non-melanoma skin cancer with promise to support primary preventative efforts in reducing non-melanoma skin cancer incidence."
11/01/2017 - "The overall aim of the thesis was to investigate if ingenol mebutate could be used as a chemopreventive agent to prevent development of non-melanoma skin cancer with minimal side effects. "